Company intelligence / Profile preview
CONNECTA Therapeutics
Barcelona, Spainconnectatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting a Phase I clinical trial to assess the safety and tolerability of CTH120 in healthy volunteers. CTH120 has shown promising results in in vitro and in vivo studies as a neuroplasticity modulator with a good ADME and safety profile in regulatory toxicology studies.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on CONNECTA Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CONNECTA Therapeutics.